6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

Inhaled pharmacotherapy delivers therapeutic compounds directly to the bronchial mucosa, maximizing localized pulmonary concentration while minimizing systemic drug exposure. However, the efficacy of aerosol delivery in pediatric patients is heavily governed by physical aerosol mechanics, airway anatomy, breathing patterns, and developmental competence. Selecting an inappropriate inhalation device or employing flawed administration technique is the leading cause of ambulatory treatment failure and preventable asthma exacerbations in children.

---

Aerosol Physics & Pulmonary Deposition Dynamics

Deposition of aerosolized particles within the respiratory tree is governed by particle size, particle velocity, airway geometry, and inspiratory flow patterns. The standardized metric utilized to characterize aerosol clouds is the Mass Median Aerodynamic Diameter (MMAD)—the diameter at which 50% of the aerosol mass resides in larger particles and 50% in smaller particles.

Aerosol Particle Size Deposition Fate:

Particle Size:    > 5 microns               1 to 5 microns             < 1 micron
              ┌───────────────────┐     ┌─────────────────────┐     ┌──────────────────┐
Mechanism:    │ Inertial Impaction│     │    Sedimentation    │     │ Brownian Motion  │
              └─────────┬─────────┘     └──────────┬──────────┘     └────────┬─────────┘
                        │                          │                         │
Fate:         Deposits in Oropharynx,   Target Bronchial &          Remains suspended;
              Larynx, and Tongue;       Lower Conducting Airways;   >80% exhaled without
              swallowed systemic loss   OPTIMAL THERAPEUTIC ZONE    deposition

Particle Size Tiers & Deposition Mechanisms

1. Particles > 5 μm (Inertial Impaction): Due to high mass and momentum, these particles cannot navigate directional changes at the posterior oropharynx, bifurcations of the trachea, or mainstem bronchi. They collide with and deposit onto mucosal surfaces of the oropharynx, tongue, and larynx. Swallowed drug undergoes gastrointestinal absorption, contributing to systemic toxicities without pulmonary benefit.
2. Particles 1 to 5 μm (Gravitational Sedimentation): This represents the respirable fraction / optimal therapeutic window. These particles possess low enough momentum to traverse the larynx and upper airway, but sufficient mass to settle out of inspired air via gravity into lower conducting airways (bronchi and terminal bronchioles).
3. Particles < 1 μm (Brownian Diffusion): Dominated by random thermal collisions with gas molecules. These ultra-fine particles remain suspended in the aerosol cloud and more than 80% are exhaled before settling onto bronchial epithelium.

Pediatric Anatomical & Physiological Differences

• Tidal Volume & Dead Space: Infants have small tidal volumes (VT ≈ 6 to 8 mL/kg) and narrow airway calibers. The absolute dose of aerosol delivered to infant lungs is naturally smaller than in adults.
• Respiratory Rate: Rapid, shallow respiratory rates in young children increase upper airway turbulence and shorten residence time in the lung, reducing gravitational sedimentation.
• Obligate Nasal Breathing: Infants under 6 months are preferential nasal breathers. The tortuous nasal turbinates act as an exceptionally efficient particle filter, removing 40% to 50% of aerosolized particles before they reach the vocal cords.

---

Developmental Inhalation Device Selection Matrix

Matching the inhalation device to the child's cognitive, physical, and developmental capability is essential. BCPPS candidates must master device selection rules across pediatric life stages:

---

Device Mechanics & Pediatric Nuances

1. Pressurized Metered-Dose Inhalers (pMDIs) with Valved Holding Chambers (VHCs)

A standard pMDI releases medication dissolved or suspended in a hydrofluoroalkane (HFA) propellant at speeds exceeding 100 km/h over a duration of 0.15 to 0.2 seconds. Without a chamber, up to 80% to 90% of the emitted dose impacts the posterior pharynx due to hand-breath dyscoordination and ballistic velocity.

• Valved Holding Chamber Architecture: A VHC incorporates a one-way inspiratory valve that opens only when the patient inhales, holding the aerosol cloud suspended for several seconds. This completely decouples actuation from inhalation, eliminating the need for hand-breath coordination.
• Facemask Dynamics in Young Children:
  • An airtight facial seal is paramount. A gap as narrow as 1 cm between the silicone mask and facial contour reduces lung drug delivery by > 50%.
  • The child must take 5 to 6 calm, normal tidal breaths through the chamber per actuation to empty the chamber volume.
• The Crying Child Paradox:
  • When an infant or toddler cries, the breathing pattern shifts to high-velocity, turbulent inspiratory gasps followed by prolonged expiratory phonation with closed vocal cords.
  • Radionucleotide deposition studies prove that crying reduces pulmonary drug deposition from ~6–10% in a calm infant to < 1 to 1.5% (a > 75% to 80% reduction).
  • Clinical Mandate: Never force an inhaler mask onto a screaming, thrashing toddler. Educate caregivers to administer medication when the child is calm, distracted with play/media, or comfortably sleeping.

Impact of Facemask Seal and Patient Demeanor on Lung Deposition:

[Calm Infant + Airtight Mask Seal]    ──► [~6% to 10% Lung Deposition] ──► Optimal Bronchodilation
[Mask Gap of only 1 cm]              ──► [>50% Reduction in Dose]     ──► Therapeutic Failure
[Vigorously Crying Toddler]          ──► [>75% to 80% Reduction]      ──► Severe Under-Dosing (<1.5%)

2. Dry Powder Inhalers (DPIs: Diskus, Flexhaler, Ellipta, Twisthaler)

DPIs are breath-actuated devices containing micronized drug blended with larger carrier particles (typically lactose monohydrate crystals).

• Inspiratory Flow Demand: De-aggregation of the micronized drug from lactose carriers requires energy generated entirely by the patient's inspiratory effort. The patient must achieve a Peak Inspiratory Flow Rate (PIFR) of at least 30 to 60 L/min against the internal airflow resistance of the device.
• Limitations in Pediatrics:
  • Children under 5 to 6 years of age cannot reliably generate the required PIFR.
  • Strictly Contraindicated in Acute Exacerbations: During severe airway obstruction, tachypnea, and diaphragmatic fatigue, even older children and adolescents cannot generate ≥30 L/min of inspiratory flow, causing the drug powder to fail de-aggregation and deposit in the mouth.
  • Humidity Sensitivity: Storing DPIs in humid environments (e.g., bathrooms) causes lactose powder clumping, drastically reducing emitted respirable mass.
  • Technique Rule: Requires a fast, forceful, deep inhalation, contrasting sharply with pMDIs which require a slow, deep inhalation over 3 to 5 seconds.

3. Soft Mist Inhalers (SMIs: Respimat)

The Respimat utilizes a mechanical spring mechanism that forces drug solution through a micro-engineered nozzle (the uniblock), producing two converging liquid jets that collide to generate an ultra-fine, slow-moving aerosol cloud.

• Velocity & Duration: Emits aerosol at 1/10th the speed of a pMDI over an extended duration of 1.2 to 1.5 seconds.
• Lung Deposition: Over 50% to 65% of the nominal dose achieves lower airway deposition (compared to 15–20% for unspaced pMDIs), with minimal oropharyngeal impaction even if actuation and inhalation are slightly asynchronous.

---

Valved Holding Chambers & Electrostatic Charge Mitigation

Standard plastic spacers and VHCs are manufactured from non-conductive polymers (e.g., polycarbonate or polypropylene). During manufacturing, handling, and dry wiping, these plastics develop intense electrostatic surface charges.

Electrostatic Charge Dynamics in Valved Holding Chambers:

[Static-Charged Plastic Chamber]      [Anti-Static or Detergent-Coated Chamber]
     ┌──────────────────┐                  ┌──────────────────┐
     │  -   -   -   -   │                  │  ~   ~   ~   ~   │
     │-  ● Aerosol    - │                  │   ● Aerosol Plume│
     │-  Attraction   - │                  │   Remains in     │
     │-  to Walls     - │                  │   Suspension     │
     │  -   -   -   -   │                  │  ~   ~   ~   ~   │
     └──────────────────┘                  └──────────────────┘
• Aerosol half-life: < 2 to 3 seconds  • Aerosol half-life: > 20 to 30 seconds
• Delivered lung dose cut by 50%       • Full respirable fraction delivered

The Physics of Electrostatic Drug Loss

• Aerosolized drug droplets carry static charges. Inside a charged plastic chamber, electrostatic attraction pulls the drug particles toward the chamber walls, where they impact and adhere.
• Electrostatic charge decreases the half-life of suspended aerosol within the chamber from >20–30 seconds down to <2–3 seconds, cutting the delivered respirable drug dose by up to 50%.

De-Electrification Protocol for Standard Plastic Chambers

1. Detergent Washing: Soak the disassembled chamber in warm water containing 2 to 3 drops of mild liquid dishwashing detergent (e.g., Dawn) for 15 minutes.
2. The Non-Ionic Surfactant Layer: Detergent molecules coat the inner plastic surface with a monomolecular surfactant layer that dissipates electrostatic charge.
3. CRITICAL CLINICAL MANDATE — DO NOT RINSE: The chamber must NOT be rinsed with clean water after the detergent bath; rinsing washes away the protective antistatic surfactant layer.
4. AIR-DRY ONLY — DO NOT WIPE: Allow the chamber to air-dry completely on a clean drying rack. Never wipe or dry the chamber with cloth towels or paper towels; friction from wiping re-introduces intense triboelectric static charge.
5. Anti-Static Chambers: Modern chambers constructed from conductive polymers or metal (e.g., AeroChamber Plus Flow-Vu, Vortex) permanently resist static charge and do not require detergent soaking protocols.

---

Prevention of Local Corticosteroid Adverse Effects

Local deposition of inhaled corticosteroids in the oral cavity and hypopharynx causes two predictable adverse effects in up to 10% to 30% of unspaced inhaler users:

1. Oropharyngeal Candidiasis (Thrush): Topical corticosteroid immunosuppression on oral mucosal epithelium enables overgrowth of Candida albicans, presenting as curd-like white plaques on the buccal mucosa, tongue, and pharynx.
2. Dysphonia: Steroid-induced chemical inflammation or myopathy of the laryngeal adductor muscles (vocal cords), presenting as hoarseness, pitch alteration, or vocal fatigue.

Prevention Strategies

• Mandatory Valved Holding Chamber Use: VHCs filter out large particles (>5 μm), reducing oropharyngeal impaction by >80% to 90%.
• The "Swish, Gargle, and Spit" Protocol: Instruct the child to vigorously rinse their mouth with water, gargle, and spit the water into the sink immediately after every ICS administration. Swallowing the rinse water promotes systemic gastrointestinal absorption.
• Facial Washing for Mask Users: When an infant or toddler receives an ICS via facemask, corticosteroids deposit onto the facial skin around the nose and mouth, causing local contact dermatitis, perioral rash, or cutaneous absorption. Caregivers must wipe the child's face with a damp washcloth and offer a drink of water or feeding immediately following each treatment.

---

Written Asthma Action Plans (AAP) & Caregiver Coaching

Every pediatric asthma patient must have a personalized, written Asthma Action Plan (AAP) shared with parents, school nurses, and daycare providers. AAPs are categorized into 3 universal color zones:

Written Asthma Action Plan (AAP) 3-Zone Architecture:

┌─────────────────────────────────────────────────────────────────────────────────┐
│ GREEN ZONE: DOING WELL                                                          │
│ • Criteria: Peak flow >80% personal best; no cough, wheeze, or nocturnal waking.│
│ • Action: Continue daily maintenance controllers (e.g., daily ICS or SMART).   │
├─────────────────────────────────────────────────────────────────────────────────┤
│ YELLOW ZONE: CAUTION (Asthma Is Getting Worse / Flare-up)                       │
│ • Criteria: Peak flow 50% to 79% personal best; cough, wheeze, mild retractions.│
│ • Action: Step up relief therapy; initiate SABA (2-4 puffs q4h) OR increase     │
│   ICS-formoterol reliever actuations under SMART protocol; contact clinician.   │
├─────────────────────────────────────────────────────────────────────────────────┤
│ RED ZONE: MEDICAL ALERT (Emergency!)                                            │
│ • Criteria: Peak flow <50% personal best; severe dyspnea, retractions, grunting.│
│ • Action: Take immediate SABA (4-6 puffs) or SMART reliever; call 911 / ED.    │
└─────────────────────────────────────────────────────────────────────────────────┘

Caregiver Coaching & Teach-Back Verification

• Clinicians must use the interactive "teach-back" method at every clinical visit. Up to 70% of caregivers and adolescents exhibit critical technique errors (e.g., failing to shake the pMDI, failing to breathe out fully before inhalation, firing multiple actuations simultaneously into a spacer, or inhaling too quickly).
• The Multi-Puff Rule: Never fire two puffs into a chamber simultaneously. Firing multiple actuations causes droplet collisions, agglomerating small particles into large unrespirable particles (>5 μm) and halving total lung delivery. Always actuate one puff at a time, taking 5 to 6 calm tidal breaths between actuations.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1 (The Crying Infant): If a clinical vignette describes a 2-year-old crying vigorously while the mother holds a nebulizer or spacer mask, the correct intervention is to soothe and calm the child before administration. Forcing inhalation during crying delivers <1.5% of the drug to the lungs due to turbulence and tachypneic short inspiratory bursts.
• Exam Trap 2 (DPI in Acute Exacerbations): Never prescribe or recommend a DPI (e.g., fluticasone Diskus, budesonide Flexhaler) for acute asthma exacerbation management. Patients in acute distress cannot generate the minimum ≥30 to 60 L/min peak inspiratory flow required to de-aggregate dry powder.
• Exam Trap 3 (Plastic Spacer Cleaning): Never instruct parents to rinse a plastic valved holding chamber with tap water after washing with detergent, and never tell them to wipe it dry with a towel. The detergent must be allowed to air-dry unrinsed to preserve the non-ionic surfactant layer that neutralizes electrostatic charge.
• Exam Trap 4 ("Blow-By" Nebulization): Holding a nebulizer mask 2 to 4 cm away from an infant's face ("blow-by") results in >90% dissipation of the aerosol into room air, delivering less than 1% to 2% of the nominal dose. Blow-by nebulization is non-therapeutic and should never be endorsed.